7 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Showing 7 of 7 clinical reviews.
A clinician-reviewed guide to tadalafil pharmacokinetics, pharmacogenomics, and dose-adjustment considerations for Black and African ancestry men with ED, BPH, or PAH, with data from ethnicity-stratified trials and PharmGKB.
Evidence-based review of tadalafil efficacy differences in Black and African ancestry populations, covering pharmacogenomics, dosing considerations, cardiovascular overlap, and clinical trial subgroup data.
Evidence-based review of how Cialis (tadalafil) performs in Hispanic and Latino populations, including pharmacogenomic factors, diabetes-related considerations, and dosing guidance.
Evidence-based review of how tadalafil pharmacokinetics, dosing, and adverse-event rates differ in East Asian populations, including CYP3A4 metabolism data, Japanese regulatory decisions, and practical prescribing guidance.
How South Asian genetics, cardiovascular risk factors, and metabolic patterns affect tadalafil (Cialis) safety, dosing, and monitoring. Evidence-based guidance with pharmacogenomic context.
A clinician-reviewed analysis of how tadalafil (Cialis) performs in Hispanic and Latino patients, covering pharmacogenomics, CYP3A4/5 variation, diabetes-related ED risk, blood pressure interactions, and ethnicity-stratified dosing guidance.
A clinician-reviewed guide to tadalafil dosing in South Asian patients, covering CYP3A4 and CYP2C9 variants, cardiovascular risk at lower BMI, drug interactions with metformin and statins, and evidence-based dose adjustment protocols.